This trial is terminated!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Ovarian Carcinoma, Fallopian Tube Cancer or Primary Peritoneal Cancer
and you are
over 18
years old
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

This is a phase-I clinical trial to determine the feasibility and safety of Cyclophosphamide/Fludarabine Lymphodepletion and an immunomodulatory combination of Interferon-alpha Bevacizumab and Aspirin followed by adoptive transfer of vaccine-primed ex vivo CD3/CD28-costimulated peripheral blood autologous T cells and vaccination with whole tumor vaccine administered intradermally in combination with Bevacizumab in patients with recurrent ovarian cancer fallopian tube or primary peritoneal cancer. (Funding Source - FDA OOPD)

Provided treatments

  • Biological: OC-DC vaccine
  • Drug: Bevacizumab
  • Drug: cyclophosphamide 300 mg/m2/d for 3 days
  • Drug: fludarabine 30 mg/m2/d for 3 days
  • Drug: ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01312376. The sponsor of the trial is Abramson Cancer Center of the University of Pennsylvania and it is looking for 18 volunteers for the current phase.
Official trial title:
A Phase-1 Trial of Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Combined With Vaccine Boost and Bevacizumab for Recurrent Ovarian Fallopian Tube or Primary Peritoneal Cancer Previously Vaccinated With Autologous Tumor Vaccine